There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ANI Pharmaceuticals (ANIP – Research Report), Boston Scientific (BSX – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
ANI Pharmaceuticals (ANIP)
Truist Financial analyst Les Sulewski assigned a Buy rating to ANI Pharmaceuticals today and set a price target of $59.13. The company’s shares closed last Monday at $60.25.
According to TipRanks.com, Sulewski is a 4-star analyst with an average return of
Currently, the analyst consensus on ANI Pharmaceuticals is a Moderate Buy with an average price target of $64.57.
See today’s best-performing stocks on TipRanks >>
Boston Scientific (BSX)
In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Boston Scientific, with a price target of $72.00. The company’s shares closed last Monday at $66.67, close to its 52-week high of $67.32.
According to TipRanks.com, O’Brien is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $68.64 average price target.
Regeneron (REGN)
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Regeneron, with a price target of $1184.00. The company’s shares closed last Monday at $989.28, close to its 52-week high of $995.97.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $1031.41, a 5.5% upside from current levels. In a report issued on February 15, Argus Research also maintained a Buy rating on the stock with a $1060.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANIP:
- Is ANIP a Buy, Before Earnings?
- ANI Pharmaceuticals Sells Ontario Facility for $14.2M USD
- ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ANI Pharmaceuticals Enhances Financial Disclosure Accessibility
- ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
